Bob Löwenberg, MD, PhD, is a Principal Investigator & Professor of Hematology in the Department of Hematology at the Erasmus University Medical Center, Erasmus University, Rotterdam, Netherlands, where he has worked since 1990. Prof. Löwenberg was Chair Cluster of Hematology-Oncology at Erasmus University Medical Center from 2000-2011.
From 1982-1990, Prof. Löwenberg was Director of Research at Daniel den Hoed Cancer Center, Rotterdam, Netherlands and from 1983-1986, he was a Visiting Professor at Free University Brussel, Brussels, Belgium. From 1990-2011, he served as the Chairman of the Department of Hematology at Erasmus University Medical Center.
Prof. Löwenberg was one of the founders and has served as President of the European Haematology Association (EHA). He has been President of the International Society of Experimental Hematology and the International Society of Hematology, and is a past Chairman of the Scientific Advisory Board and current Vice-President of the Board of the European School of Hematology in Paris, France. He also founded and served as the first President of the Dutch-Belgian Cooperative Group on Hemato-Oncology in Adults (HOVON Cooperative Group).
Speaking on personalized treatment for patients with leukemia
Currently, Prof. Löwenberg is participating in research concerning molecular diagnostics for acute myeloid leukemia (AML). He is also involved in a project which is focusing on advancing NGS-based prediction of relapse in AML in relation to clonal hematopoiesis.